WallStreetZenWallStreetZen

NASDAQ: TGTX
Tg Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TGTX stock forecasts and price targets.

Forecast return on equity

Is TGTX forecast to generate an efficient return?

Company
189.41%
Industry
130.77%
Market
-49.74%
TGTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TGTX forecast to generate an efficient return on assets?

Company
74.52%
Industry
47.39%
TGTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TGTX earnings per share forecast

What is TGTX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.77+87.39%
Avg 2 year Forecast
$1.74+324.8%
Avg 3 year Forecast
$2.15+425.2%
TGTX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

TGTX revenue forecast

What is TGTX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$583.8M+28.56%
Avg 2 year Forecast
$753.8M+66.02%
Avg 3 year Forecast
$984.7M+116.87%
TGTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TGTX earnings growth forecast

How is TGTX forecast to perform vs Biotechnology companies and vs the US market?

Company
78.04%
Industry
5.14%
Market
15.23%
TGTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
TGTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
TGTX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

TGTX revenue growth forecast

How is TGTX forecast to perform vs Biotechnology companies and vs the US market?

Company
29.44%
Industry
85.29%
Market
10.87%
TGTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TGTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TGTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TGTX$31.99N/AN/A
MRUS$66.90$98.80+47.68%Strong Buy
RNA$41.44$69.82+68.48%Strong Buy
ABVX$82.28$98.86+20.15%Strong Buy
PTCT$59.69$72.36+21.23%Strong Buy
View Top Biotech Stocks

Tg Therapeutics Stock Forecast FAQ

What is TGTX's earnings growth forecast for 2025-2027?

(NASDAQ: TGTX) Tg Therapeutics's forecast annual earnings growth rate of 78.04% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Tg Therapeutics's earnings in 2025 is $60,458,000.On average, 6 Wall Street analysts forecast TGTX's earnings for 2025 to be $121,902,790, with the lowest TGTX earnings forecast at $84,092,775, and the highest TGTX earnings forecast at $152,318,988. On average, 6 Wall Street analysts forecast TGTX's earnings for 2026 to be $276,347,898, with the lowest TGTX earnings forecast at $165,012,238, and the highest TGTX earnings forecast at $395,077,376.

In 2027, TGTX is forecast to generate $341,654,664 in earnings, with the lowest earnings forecast at $269,731,542 and the highest earnings forecast at $377,624,159.

If you're new to stock investing, here's how to buy Tg Therapeutics stock.

What is TGTX's revenue growth forecast for 2025-2027?

(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 29.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.87%.

Tg Therapeutics's revenue in 2025 is $454,068,000.On average, 2 Wall Street analysts forecast TGTX's revenue for 2025 to be $92,621,844,917, with the lowest TGTX revenue forecast at $91,155,139,990, and the highest TGTX revenue forecast at $94,088,708,509. On average, 3 Wall Street analysts forecast TGTX's revenue for 2026 to be $119,607,375,045, with the lowest TGTX revenue forecast at $109,891,962,229, and the highest TGTX revenue forecast at $129,217,275,227.

In 2027, TGTX is forecast to generate $156,244,375,746 in revenue, with the lowest revenue forecast at $140,374,799,799 and the highest revenue forecast at $168,375,948,516.

What is TGTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TGTX) forecast ROA is 74.52%, which is higher than the forecast US Biotechnology industry average of 47.39%.

What is TGTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TGTX) Tg Therapeutics's current Earnings Per Share (EPS) is $0.41. On average, analysts forecast that TGTX's EPS will be $0.77 for 2025, with the lowest EPS forecast at $0.53, and the highest EPS forecast at $0.96. On average, analysts forecast that TGTX's EPS will be $1.74 for 2026, with the lowest EPS forecast at $1.04, and the highest EPS forecast at $2.49. In 2027, TGTX's EPS is forecast to hit $2.15 (min: $1.70, max: $2.38).

What is TGTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TGTX) forecast ROE is 189.41%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.